CILENGITIDE

Cilengitide Adverse Events Reported to the FDA Over Time

How are Cilengitide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cilengitide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cilengitide is flagged as the suspect drug causing the adverse event.

Most Common Cilengitide Adverse Events Reported to the FDA

What are the most common Cilengitide adverse events reported to the FDA?

Neutropenia	17 (4.18%)
Thrombocytopenia	16 (3.93%)
Pulmonary Embolism	15 (3.69%)
Syncope	15 (3.69%)
Hypotension	14 (3.44%)
Hyponatraemia	11 (2.7%)
Stomatitis	11 (2.7%)
Fatigue	10 (2.46%)
Hypokalaemia	10 (2.46%)
Leukopenia	10 (2.46%)
Febrile Neutropenia	9 (2.21%)
	Show More
Pneumonitis	9 (2.21%)
Sepsis	9 (2.21%)
Arteriosclerosis	8 (1.97%)
Visual Acuity Reduced	8 (1.97%)
Deep Vein Thrombosis	7 (1.72%)
Diarrhoea	7 (1.72%)
Dyspnoea	7 (1.72%)
Mucosal Inflammation	7 (1.72%)
Vomiting	7 (1.72%)
Acute Hepatic Failure	6 (1.47%)
Blood Amylase Increased	6 (1.47%)
Epistaxis	6 (1.47%)
Hypoxia	6 (1.47%)
Pulmonary Thrombosis	6 (1.47%)
Aortic Thrombosis	5 (1.23%)
Decreased Appetite	5 (1.23%)
Haemoglobin Decreased	5 (1.23%)
Oedema Peripheral	5 (1.23%)
Pancytopenia	5 (1.23%)
Pneumonia	5 (1.23%)
Pyrexia	5 (1.23%)
Sudden Death	5 (1.23%)
Thrombosis	5 (1.23%)
Acute Respiratory Distress Syndrome	4 (.98%)
Arrhythmia Supraventricular	4 (.98%)
Death	4 (.98%)
Dehydration	4 (.98%)
Hypocalcaemia	4 (.98%)
Renal Impairment	4 (.98%)
Retinal Artery Occlusion	4 (.98%)
Thrombophlebitis Superficial	4 (.98%)
Ventricular Tachycardia	4 (.98%)
Cerebrovascular Accident	3 (.74%)
Deafness	3 (.74%)
Escherichia Sepsis	3 (.74%)
Gastrointestinal Infection	3 (.74%)
Haematochezia	3 (.74%)
Pulmonary Artery Thrombosis	3 (.74%)
Convulsion	2 (.49%)
Diverticulitis	2 (.49%)
Drug Toxicity	2 (.49%)
Duodenal Ulcer	2 (.49%)
Haematocrit Decreased	2 (.49%)
Hypomagnesaemia	2 (.49%)
Hypovolaemic Shock	2 (.49%)
Large Intestine Perforation	2 (.49%)
Malaise	2 (.49%)
Metastases To Central Nervous Syste...	2 (.49%)
Nausea	2 (.49%)
Peripheral Embolism	2 (.49%)
Pulmonary Sepsis	2 (.49%)
Renal Failure	2 (.49%)
Vertigo	2 (.49%)
White Blood Cell Count Decreased	2 (.49%)
Acute Myocardial Infarction	1 (.25%)
Anaemia	1 (.25%)
Arteriosclerosis Coronary Artery	1 (.25%)
Blood Chloride Decreased	1 (.25%)
Blood Pressure Decreased	1 (.25%)
Blood Sodium Decreased	1 (.25%)
Blood Urea Increased	1 (.25%)
Bone Marrow Failure	1 (.25%)
Brain Oedema	1 (.25%)
Cachexia	1 (.25%)
Chronic Obstructive Pulmonary Disea...	1 (.25%)
Coronary Artery Stenosis	1 (.25%)
Diabetic Foot	1 (.25%)
Embolism	1 (.25%)
Emphysema	1 (.25%)
Gamma-glutamyltransferase Increased	1 (.25%)
Gastritis Erosive	1 (.25%)
General Physical Health Deteriorati...	1 (.25%)
Glomerular Filtration Rate Decrease...	1 (.25%)
Hydrocephalus	1 (.25%)
Infection	1 (.25%)
Metastases To Lung	1 (.25%)
Multi-organ Failure	1 (.25%)
Muscle Spasms	1 (.25%)
Neoplasm Malignant	1 (.25%)
Nephrosclerosis	1 (.25%)
Oesophageal Ulcer	1 (.25%)
Peripheral Arterial Occlusive Disea...	1 (.25%)
Platelet Count Decreased	1 (.25%)
Platelet Count Increased	1 (.25%)
Renal Failure Acute	1 (.25%)
Renal Failure Chronic	1 (.25%)
Squamous Cell Carcinoma Of Skin	1 (.25%)
Staphylococcal Infection	1 (.25%)
Transaminases Increased	1 (.25%)
Urinary Tract Infection	1 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Cilengitide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cilengitide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cilengitide

What are the most common Cilengitide adverse events reported to the FDA?

White Blood Cell	36 (8.85%)
Electrolyte And Fluid Balance Condi...	25 (6.14%)
Embolism And Thrombosis	25 (6.14%)
Pulmonary Vascular	24 (5.9%)
Infections - Pathogen Unspecified	23 (5.65%)
Decreased And Nonspecific Blood Pre...	16 (3.93%)
Platelet	16 (3.93%)
Neurological	15 (3.69%)
Lower Respiratory Tract Disorders	14 (3.44%)
Respiratory	13 (3.19%)
Hematology Investigations	12 (2.95%)
	Show More
Oral Soft Tissue Conditions	11 (2.7%)
Arteriosclerosis, Stenosis, Vascula...	9 (2.21%)
Fatal Outcomes	9 (2.21%)
Gastrointestinal Signs	9 (2.21%)
Cardiac Arrhythmias	8 (1.97%)
Renal Disorders	8 (1.97%)
Vision	8 (1.97%)
Anemias Nonhemolytic And Marrow Dep...	7 (1.72%)
Gastrointestinal Motility And Defec...	7 (1.72%)
Appetite And General Nutritional	6 (1.47%)
Bone, Calcium, Magnesium And Phosph...	6 (1.47%)
Gastrointestinal	6 (1.47%)
Gastrointestinal Ulceration And Per...	6 (1.47%)
Hepatic And Hepatobiliary	6 (1.47%)
Upper Respiratory Tract Disorders	6 (1.47%)
Body Temperature Conditions	5 (1.23%)
Bacterial Infectious	4 (.98%)
Retina, Choroid And Vitreous Hemorr...	4 (.98%)
Central Nervous System Vascular	3 (.74%)
Coronary Artery	3 (.74%)
Gastrointestinal Hemorrhages	3 (.74%)
Hearing	3 (.74%)
Metastases	3 (.74%)
Chemical Injury And Poisoning	2 (.49%)
Hepatobiliary	2 (.49%)
Increased Intracranial Pressure And...	2 (.49%)
Inner Ear And Viiith Cranial Nerve	2 (.49%)
Renal And Urinary Tract Investigati...	2 (.49%)
Seizures	2 (.49%)
Water, Electrolyte And Mineral	2 (.49%)
Bronchial Disorders	1 (.25%)
Cardiac And Vascular Investigations	1 (.25%)
Diabetic Complications	1 (.25%)
Miscellaneous And Site Unspecified ...	1 (.25%)
Muscle	1 (.25%)
Nephropathies	1 (.25%)
Physical Examination Topics	1 (.25%)
Skin Neoplasms Malignant And Unspec...	1 (.25%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cilengitide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cilengitide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.